Sunesis Pharmaceuticals Stock Price

0.15 (11.54%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
DDE w/Realtime (Monthly)
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Sunesis Pharmaceuticals Inc SNSS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.15 11.54% 1.45 00:00:08
Close Price Low Price High Price Open Price Previous Close
1.455 1.28 1.55 1.31 1.30
Bid Price Ask Price Spread News
1.38 2.40 1.02 - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
4,855 2,006,251 $ 1.44 $ 2,887,120 719,536 0.161 - 2.25
Last Trade Time Type Quantity Stock Price Currency
19:57:59 25 $ 1.40 USD

Sunesis Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 26.23M 18.09M 17.58M $ 2.07M $ - -2.90 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 1.10%

more financials information »

Sunesis Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical SNSS Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week1.331.551.281.34354,8440.129.02%
1 Month1.171.551.171.34606,9800.2823.93%
3 Months0.282.250.1610.35760687,824,2191.17417.86%
6 Months0.45242.250.1610.35523797,658,6270.9976220.51%
1 Year0.55522.250.1610.38600474,777,6480.8948161.17%
3 Years1.967.690.1610.54493621,931,923-0.51-26.02%
5 Years0.897.690.1610.60328831,246,7720.5662.92%

Sunesis Pharmaceuticals Description

Sunesis Pharmaceuticals Inc is a US-based biopharmaceutical company. It focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The product portfolio of the company includes Vosaroxin which is an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). The company's other kinase inhibitor pipeline includes TAK-580, SNS-062, and SNS-229. Further, the firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The firm derives substantially the majority of revenue from license and collaboration agreements.

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.